Recent Updates
Recently added Catalysts
ECOR Positive Sentiment

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Key Takeaway: electroCore, Inc. announced the appointment of Jennifer Hayes as Vice President of Human Resources, effective October 6, 2025. In connection with her employment, the company granted her 10,000 restricted stock units (RSUs) under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on her continued employment.
Price reaction · baseline $5.01 (2025-10-03 close) · hit after-hours · clean, no other ECOR news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Jennifer Hayes as VP of Human Resources.
  • Granting of 10,000 RSUs as an inducement for new employment.
  • Company continues to expand its leadership team.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
GammaCore
Phase 2 · Chronic Cluster Headache

Full Press Release Details

ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were granted as an inducement material to Ms. Hayes’ commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). One-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Ms. Hayes’ continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.
About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visitwww.electrocore.com.

Contact:ECOR Investor Relations(973) 302-9253investors@electrocore.com

Frequently Asked Questions

Who is Jennifer Hayes?

Jennifer Hayes is the newly appointed Vice President of Human Resources at electroCore.

What is the significance of the RSUs granted?

The 10,000 RSUs were granted as an inducement for Jennifer Hayes' employment under NASDAQ rules.

When will the RSUs vest?

The RSUs will vest in three equal parts over three years, contingent on continued employment.

What does electroCore specialize in?

electroCore specializes in bioelectronic medicine and wellness technologies.

Last updated: Oct 3, 2025